Literature DB >> 8038415

RU486: pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri.

A A Murphy1, P Z Castellano.   

Abstract

More than a decade after the serendipidous discovery of RU486, numerous antiprogestins have been synthesized and studied. Interest in how antiprogestins exert their antagonist effect has led to novel information about the molecular mechanisms of progesterone action. The pivotal role that progesterone plays in reproductive biology has led to research in many areas where a potential role for these compounds may be found in health and disease. RU486 has been shown to relieve pelvic pain associated with endometriosis and to decrease American Fertility Society endometriosis scores. Uterine leiomyomata show a significant reduction in size after administration of RU486 for 3 months. Although much research remains to be carried out, RU486 appears promising as alternative therapies for these diseases.

Entities:  

Keywords:  Biology; Cancer; Diseases; Endocrine System; Endometrial Effects; Endometrium; Estrogens; Fibroids; Genitalia; Genitalia, Female; Hormone Antagonists; Hormones; Literature Review; Neoplasms; Neoplasms, Benign; Physiology; Progestational Hormones; Progesterone; Ru-486--pharmacodynamics; Ru-486--therapeutic use; Treatment; Urogenital System; Uterine Effects; Uterus

Mesh:

Substances:

Year:  1994        PMID: 8038415

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  8 in total

Review 1.  Proven and potential clinical applications of mifpristone (RU486).

Authors:  Irving M Spitz
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

Review 2.  Progesterone receptor action in leiomyoma and endometrial cancer.

Authors:  J Julie Kim; Elizabeth C Sefton; Serdar E Bulun
Journal:  Prog Mol Biol Transl Sci       Date:  2009-10-07       Impact factor: 3.622

3.  Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.

Authors:  Yongli Ji; Cathryn Rankin; Steven Grunberg; Andy E Sherrod; Jamshid Ahmadi; Jeannette J Townsend; Lynn G Feun; Ruth K Fredericks; Christy A Russell; Fairooz F Kabbinavar; Keith J Stelzer; Anne Schott; Claire Verschraegen
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

Review 4.  Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer.

Authors:  J Julie Kim; Takeshi Kurita; Serdar E Bulun
Journal:  Endocr Rev       Date:  2013-01-09       Impact factor: 19.871

5.  A study evaluating the effect of mifepristone (RU-486) for the treatment of leiomyomata uteri.

Authors:  Sucheta Mukherjee; Somajita Chakraborty
Journal:  Niger Med J       Date:  2011-07

Review 6.  Antiprogestins in gynecological diseases.

Authors:  Alicia A Goyeneche; Carlos M Telleria
Journal:  Reproduction       Date:  2014-09-24       Impact factor: 3.906

7.  Mifepristone in Fibroids: Comparative Study of Safety and Efficacy of Biweekly Dosage Vs Daily Dosage Schedule.

Authors:  Neelofar Shaikh; Reeti Mehra; Poonam Goel; Ravinder Kaur
Journal:  J Midlife Health       Date:  2021-04-17

8.  Application of a Patient Derived Xenograft Model for Predicative Study of Uterine Fibroid Disease.

Authors:  Martin Fritsch; Nicole Schmidt; Ina Gröticke; Anna-Lena Frisk; Christopher S Keator; Markus Koch; Ov D Slayden
Journal:  PLoS One       Date:  2015-11-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.